The estimated Net Worth of Amy C. Peterson is at least $4.77 Million dollars as of 16 March 2023. Amy Peterson owns over 4,257 units of CytomX Therapeutics Inc stock worth over $76,547 and over the last 8 years he sold CTMX stock worth over $1,293,419. In addition, he makes $3,395,720 as Executive Vice President and Chief Development Officer at CytomX Therapeutics Inc.
Amy has made over 6 trades of the CytomX Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 4,257 units of CTMX stock worth $8,429 on 16 March 2023.
The largest trade he's ever made was exercising 40,000 units of CytomX Therapeutics Inc stock on 8 November 2018 worth over $1,164,000. On average, Amy trades about 4,055 units every 97 days since 2016. As of 16 March 2023 he still owns at least 58,433 units of CytomX Therapeutics Inc stock.
You can see the complete history of Amy Peterson stock trades at the bottom of the page.
Dr. Amy C. Peterson, M.D. is Executive Vice President, Chief Development Officer of the Company. Dr. Peterson was chief medical officer of immuno-oncology at BeiGene Ltd., where she created and led a global oncology development organization with direct medical oversight and accountability of seven clinical assets in over thirty global trials in all phases of development in solid tumor indications. Prior to BeiGene, from August 2011 to July 2016, Dr. Peterson was vice president of clinical development at Medivation, where she was primarily responsible for the development of enzalutamide (XTANDI®) and talazoparib (TALZENNA®) in breast cancer. Previously, Dr. Peterson served as associate group medical director at Genentech from 2005 to 2011, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology. Prior to joining Genentech, Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski. She currently serves on the board of The American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation. Dr. Peterson received her M.D. from Thomas Jefferson University and completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. Dr. Peterson received her B.A. degree from Wesleyan University.
As the Executive Vice President and Chief Development Officer of CytomX Therapeutics Inc, the total compensation of Amy Peterson at CytomX Therapeutics Inc is $3,395,720. There are 1 executives at CytomX Therapeutics Inc getting paid more, with Sean McCarthy having the highest compensation of $3,769,930.
Amy Peterson is 53, he's been the Executive Vice President and Chief Development Officer of CytomX Therapeutics Inc since 2019. There are 14 older and 3 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
Amy's mailing address filed with the SEC is 1851 HARBOR BAY PARKWAY, , ALAMEDA, CA, 94502.
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca..., and James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: